Advanced Search
Contact | Corporate | Help

RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM

Sponsors:
  • Sarah Cannon Research Institute
  • Genentech
  • Novartis
Phases:
  • Phase II
IndicationsAcronym:
  • Glioblastoma Multiforme
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Radiation: Radiation therapy
  • Drug: Temozolomide
  • Drug: Bevacizumab
  • Drug: Bevacizumab
  • Drug: Everolimus
Enrollment:
60

Additional information about NCT00805961.


SourceSolution © 2008-2012